Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2016 0 · FY2017 0 · FY2018 0
Operates in Healthcare Services — General medicine - private practice. Per the activity note to the FY2024 annual report, the company provides comprehensive medical services including laboratory, dermatology, endocrinology, neurology, and oncology services. Founded in 2011. Offers full-service ambulatory laboratory and medical specialist consultations.
| Ratio | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Margins | ||||||||
| Gross Margin | 87.9% | 96.5% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| EBITDA Margin | 74.1% | -5.0% | -6.8% | 5.5% | 6.4% | 4.0% | 9.1% | 12.8% |
| EBITDAR | 8,160 | 11 | 247 | 996 | 1,192 | 997 | 1,525 | 2,350 |
| EBITDAR Margin | 75.3% | 0.2% | 4.1% | 15.7% | 16.1% | 14.1% | 19.4% | 20.5% |
| EBIT Margin | 63.9% | -10.1% | -10.9% | 2.0% | 3.7% | 0.7% | 6.9% | 10.5% |
| Net Profit Margin | 1.5% | 0.2% | -8.2% | 4.5% | 7.7% | 4.8% | 7.1% | -1.9% |
| Operating Expense % of Sales | 13.8% | 101.5% | 106.8% | 94.5% | 93.6% | 96.0% | 90.9% | 87.2% |
| Returns | ||||||||
| Return on Assets (ROA) | 1.3% | 0.5% | -20.3% | 10.6% | 21.6% | 12.5% | 20.0% | -1.4% |
| Return on Equity (ROE) | 8.2% | 1.2% | -56.4% | 24.8% | 55.7% | 24.7% | 51.8% | -13.9% |
| ROIC [EBIT / Invested Capital] | 67.5% | -54.0% | -64.2% | 9.5% | 25.0% | 4.7% | 31.6% | 8.5% |
| Leverage & debt balances | ||||||||
| Debt-to-Assets | 66.3% | 11.1% | 15.8% | 18.4% | 12.4% | 10.0% | 30.3% | 81.9% |
| Debt-to-Equity | 4.26x | 0.26x | 0.44x | 0.43x | 0.32x | 0.20x | 0.79x | 8.27x |
| Debt-to-EBITDA | 1.07x | N/A | N/A | 1.43x | 0.69x | 0.95x | 1.18x | 8.78x |
| Equity-to-Assets | 15.6% | 43.0% | 36.0% | 42.7% | 38.8% | 50.7% | 38.5% | 9.9% |
| Net Debt | 8,230 | 129 | 145 | 184 | 79 | -314 | 627 | 12,620 |
| Cash & Equivalents | 379 | 100 | 236 | 315 | 247 | 583 | 226 | 313 |
| Total Debt | 8,609 | 230 | 381 | 499 | 326 | 269 | 853 | 12,933 |
| Liquidity & working capital | ||||||||
| Current Ratio | 0.33x | 0.82x | 0.63x | 0.95x | 0.80x | 1.02x | 0.83x | 0.70x |
| Quick Ratio | 0.33x | 0.82x | 0.59x | 0.93x | 0.80x | 1.02x | 0.83x | 0.70x |
| Cash Ratio | 0.05x | 0.10x | 0.16x | 0.21x | 0.17x | 0.49x | 0.15x | 0.14x |
| Total Current Assets | 2,489 | 850 | 916 | 1,410 | 1,197 | 1,214 | 1,280 | 1,593 |
| Total Current Liabilities | 7,440 | 1,035 | 1,461 | 1,489 | 1,499 | 1,192 | 1,535 | 2,278 |
| Inventory | N/A | N/A | 50 | 28 | N/A | N/A | N/A | N/A |
| Trade Receivables | 1,731 | 588 | 607 | 1,043 | 869 | 530 | 949 | 995 |
| Trade Payables | 1,079 | 535 | 1,128 | 737 | 1,114 | 899 | 698 | 844 |
| Net Working Capital | -4,951 | -184 | -545 | -79 | -302 | 21 | -255 | -685 |
| Net Working Capital % of Revenue | -45.7% | -3.4% | -9.1% | -1.2% | -4.1% | 0.3% | -3.2% | -6.0% |
| Trade Working Capital | 652 | 54 | -471 | 334 | -245 | -369 | 252 | 150 |
| Trade Working Capital % of Revenue | 6.0% | 1.0% | -7.9% | 5.3% | -3.3% | -5.2% | 3.2% | 1.3% |
| Change in Trade Working Capital | N/A | -599 | -525 | 806 | -579 | -124 | 621 | -101 |
| Turnover & efficiency | ||||||||
| Inventory Turnover | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Receivables Turnover | 6.26x | 9.28x | 9.87x | 6.09x | 8.51x | 13.36x | 8.30x | 11.54x |
| Days Sales Outstanding (DSO) | 58.3 | 39.3 | 37.0 | 59.9 | 42.9 | 27.3 | 44.0 | 31.6 |
| Payables Turnover | 1.21x | 0.36x | N/A | N/A | N/A | N/A | N/A | N/A |
| Days Payable Outstanding (DPO) | 301.2 | 1007.7 | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Conversion Cycle | -242.9 days | -968.4 days | 37.0 days | 59.9 days | 42.9 days | 27.3 days | 44.0 days | 31.6 days |
| Asset Turnover | 0.83x | 2.64x | 2.48x | 2.35x | 2.80x | 2.63x | 2.80x | 0.73x |
| Cash flow & dividends | ||||||||
| Operating Cash Flow | 1,242 | 731 | 61 | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow (OCF − Capex proxy) | 1,242 | -306 | 5 | N/A | N/A | N/A | N/A | N/A |
| Cash Conversion (OCF / EBITDA) | 15.5% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends Declared | 0 | 0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | 0.0% | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →